Oxaliplatin versus Mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study
- 43 Downloads
Background and objectives
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can offer selected patients with colorectal peritoneal metastases (CRPM) a favorable long-term survival. While cytoreductive techniques are standardized, there remains great variability in HIPEC drugs with mitomycin C or oxaliplatin use based largely on institute preference. In this study, we compared outcomes based on mitomycin C or oxaliplatin use after complete cytoreduction.
This is a retrospective analysis over a 7-year period of all patients undergoing complete cytoreduction with HIPEC.
Seventy-eight patients underwent complete cytoreduction with HIPEC during this time. Forty-six patients received oxaliplatin as HIPEC, and 32 received mitomycin C. There was no difference in patient characteristics, resections, or major morbidity between the two groups. Superficial wound infections were higher in the mitomycin C group (37.5% v 15.2%, p = 0.02). Median overall and disease-free survival for the entire cohort was 40 and 14 months, respectively. There was no difference in overall survival or disease-free survival between the two HIPEC groups (HR 0.50, 95% CI 0.11–2.28).
Complete cytoreduction and HIPEC can offer selected patients a favorable survival. The choice of mitomycin C or oxaliplatin for HIPEC had no influence on survival. Prospective studies are needed to explore this important issue.
KeywordsColorectal peritoneal metastases Peritonectomy Cytoreduction Hyperthermic intraperitoneal chemotherapy Oxaliplatin HIPEC
VN, SW, MM, RR, and AH produced the study concept and design. VN performed the scientific literature search. VN did the data collection and statistical analysis. All the authors were involved in refining the study design and data interpretation. VN, SW, MM, RR, and AH wrote the initial draft, with all the authors involved in the editing process and final version of the manuscript. All the authors have reviewed and approved the final manuscript. All the authors agree to be accountable for all aspects of the work.
Compliance with Ethical Standards
Peter MacCallum Cancer Centre institutional ethics was provided to conduct this comparative study.
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 1.Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;0:1-31.Google Scholar
- 2.AIHW. Australian Institute of Health and Welfare; Cancer in Australia 2017. Cancer series no. 101. Canberra2017.Google Scholar
- 4.Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709-19.CrossRefGoogle Scholar
- 8.Alzahrani NA, Valle SJ, Fisher OM, Sugarbaker PH, Yonemura Y, Glehen O, et al. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience. J Surg Oncol. 2018.Google Scholar
- 9.Verwaal V, van Ruth S, de Bree E, van Slooten G, van Tinteren H, Boot H, et al. Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer. J Clin Oncol. 2003;21(20):3737-43.CrossRefGoogle Scholar
- 10.Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284-92.CrossRefGoogle Scholar
- 12.Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63-8.CrossRefGoogle Scholar
- 14.Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, et al. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. Ann Surg Oncol. 2014;21(13):4195-201.CrossRefGoogle Scholar
- 19.Yurttas C, Hoffmann G, Tolios A, Haen SP, Schwab M, Konigsrainer I, et al. Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer. J Clin Med. 2018;7(12).Google Scholar
- 21.van Eden WJ, Kok NFM, Woensdregt K, Huitema ADR, Boot H, Aalbers AGJ. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2018;44(2):220-7.CrossRefGoogle Scholar
- 22.Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;36(Suppl; abstr LBA3503).Google Scholar
- 23.Cavaliere F, De Simone M, Virzi S, Deraco M, Rossi CR, Garofalo A, et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol. 2011;37(2):148-54.CrossRefGoogle Scholar
- 27.Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010;116(24):5608-18.CrossRefGoogle Scholar
- 29.Kozman M, Fisher O, Rebolledo B, Parikh R, Valle S, Arrowaili A, et al. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy. J Surg Oncol. 2018;117:725-36.CrossRefGoogle Scholar
- 34.Prada-Villaverde A, Esquivel J, Lowy A, Markman M, Chua T, Pelz J, et al. The American Society of Peritoneal Surface Malignancies Evaluation of HIPEC with Mitomycin C Versus Oxaliplatin in 539 Patients with Colon Cancer Undergoing a Complete Cytoreductive Surgery. J Surg Oncol. 2014;110:779-85.CrossRefGoogle Scholar
- 39.de Jong LAW, Elekonawo FMK, de Reuver PR, Bremers AJA, de Wilt JHW, Jansman FGA, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure. Br J Clin Pharmacol. 2019;85(1):47-58.CrossRefGoogle Scholar